Please ensure Javascript is enabled for purposes of website accessibility

Overcoming the Bottleneck in Cell and Gene Therapy Manufacturing

Cell Therapy, Medical & Life Sciences

The following is a synopsis of an article published in HIT Consultant. Click here to read the full article.

Cell and gene therapies hold immense promise for treating cancer, autoimmune disorders, and other conditions by utilizing living cells to precisely target diseases. Despite rapid scientific advancements, manufacturing these therapies remains costly and slow, creating a significant access gap. In 2020, about half a million U.S. patients were eligible for CAR T-cell therapies, yet only 3,000 commercial doses were produced, meaning only 0.6% of eligible patients received treatment. As regulatory approvals for cell therapies increase and cancer rates rise, this manufacturing bottleneck will worsen.

Currently, cell therapy manufacturing relies heavily on open systems where tasks are manually performed by skilled personnel. Producing a single therapy for one patient involves more than 50 manual processing steps, contributing to a high turnover rate of 70% in the industry. Manual processes are prone to errors, contamination, and variability, making it difficult to maintain consistent quality and scale production efficiently.

Closed manufacturing systems offer a promising solution by utilizing sophisticated bioreactors and bioprocessing equipment within a sealed, aseptic environment. Automation plays a crucial role in streamlining production, reducing manual intervention, and minimizing errors. Real-time monitoring and control of critical process parameters ensure the safety and efficacy of treatments. Closed systems address the access gap by enabling the production of both off-the-shelf and patient-specific therapies.

Additionally, closed systems facilitate decentralized cell therapy production by replicating quality standards more effectively than manual systems. This allows for smaller-scale manufacturing facilities closer to patient populations, reducing reliance on centralized hubs. Localized production minimizes transportation time and increases care accessibility, particularly in remote areas. It also offers flexibility in scaling capacity to meet demand variations and ensures compliance with transportation and distribution regulations.

The benefits of closed manufacturing systems extend beyond cell therapy, offering a blueprint for innovation across biomanufacturing. Automation, real-time monitoring, and process control principles can be applied to producing biologics, vaccines, and other advanced therapeutics. By providing scalability, standardization, and efficiency, closed systems are poised to deliver the full potential of cell-based treatments, ushering in a new era of personalized medicine.

Closed manufacturing systems are crucial for making life-saving therapies more affordable and accessible. As we continue to explore cellular biology and harness regenerative medicine, integrating automation and closed systems will be essential. Embracing closed systems will bridge the gap between scientific breakthroughs and widespread patient access, ensuring revolutionary treatments reach all those in need.

Get started
with Ascential

Speak with an Expert